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Abstract
Background: Trauma contributes to psychosis and in psychotic disorders post-traumatic stress disorder (PTSD) is
often a comorbid disorder. A problem is that PTSD is underdiagnosed and undertreated in people with psychotic
disorders. This study’s primary goal is to examine the efficacy and safety of prolonged exposure and eye movement
desensitization and reprocessing (EMDR) for PTSD in patients with both psychotic disorders and PTSD, as compared
to a waiting list. Secondly, the effects of both treatments are determined on (a) symptoms of psychosis, in particular
verbal hallucinations, (b) depression and social performance, and (c) economic costs. Thirdly, goals concern links
between trauma exposure and psychotic symptomatology and the prevalence of exposure to traumatic events, and
of PTSD. Fourthly predictors, moderators, and mediators for treatment success will be explored. These include
cognitions and experiences concerning treatment harm, credibility and burden in both participants and therapists.
Methods/Design: A short PTSD-screener assesses the possible presence of PTSD in adult patients (21- to 65- years
old) with psychotic disorders, while the Clinician Administered PTSD Scale interview will be used for the diagnosis
of current PTSD. The M.I.N.I. Plus interview will be used for diagnosing lifetime psychotic disorders and mood
disorders with psychotic features. The purpose is to include consenting participants (N = 240) in a multi-site single
blind randomized clinical trial. Patients will be allocated to one of three treatment conditions (N = 80 each):
prolonged exposure or EMDR (both consisting of eight weekly sessions of 90 minutes each) or a six-month waiting
list. All participants are subjected to blind assessments at pre-treatment, twomonths post treatment, and six
monthspost treatment. In addition, participants in the experimental conditions will have assessments at mid
treatment and at 12 months follow-up.
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Discussion: The results from the post treatment measurement can be considered strong empirical indicators of the
safety and effectiveness of prolonged exposure and EMDR. The six-month and twelve-month follow-up data have
the potential of reliably providing documentation of the long-term effects of both treatments on the various
outcome variables. Data from pre-treatment and midtreatment can be used to reveal possible pathways of change.
Trial registration: Current Controlled Trials: ISRCTN79584912
Keywords: Psychosis, PTSD, Trauma, Schizophrenia, Hallucinations, Working memory, Prolonged exposure, EMDR,
Economic evaluation, Moderators, Mediators
Background
Links between trauma, PTSD and psychosis
Of patients who have ever experienced psychotic epi-
sodes, 50% to 98% report having been exposed to one or
more traumatic events in their lives [1]. As a result, the
prevalence of post traumatic stress disorder (PTSD) in
people with psychotic disorders ranges from 12% to 29%
[2,3]. This can be considered high compared to esti-
mated prevalence rates in the general population, which
range from 0.4% to 3.5% [4-6].
In a meta-analytical study evidence was found that major
adversities in childhood (before the 18th year of life)
increase the risk of psychosis by 2.8 times on average [7]. A
dose–response relationship was found in almost all studies:
the more severe the trauma, the greater the risk of deve-
loping psychosis. Childhood trauma as a major risk factor
probably adds 33% to the onset of psychosis in society [7].
Significant associations between all types of childhood
adversities (except the loss of a parent) and symptoms of
paranoia and auditory hallucinations have been reported
[7,8]. Childhood sexual abuse is associated with hallucina-
tions (odds ratio (OR) 8.9, confidence interval (CI) = 1.86
to 42.44), and being brought up in institutional care
is specifically associated with paranoia (OR = 11.08,
CI = 3.26 to 37.62 [8].
Traumatic events, PTSD and psychosis appear to have
several interactions. The presence of a comorbid PTSD
has been found to have a negative impact on the course
and prognosis of the psychotic disorder [9], and the com-
bination of psychosis and PTSD appears to be associated
with poorer social functioning and greater risk of relapsing
in psychosis [9-11]. There are also indications that the
content of hallucinations may fully match that of experi-
enced traumas (12.5%) or the themes of hallucinations can
be very similar to that of experienced traumas (45%) [12].
The occurrence of re-experiencing symptoms of PTSD is
strongly associated with a predisposition to hallucinations.
Negative beliefs about self and others have been found to
be associated with a predisposition to paranoia [13].
There is also evidence to suggest that experiencing a
psychotic episode, and experiencing problems with the
health care system, may potentially be experienced as
traumatic events and may result in PTSD [13-15].
Considering these findings and being aware that PTSD
in general is associated with forms of non-effective cop-
ing, more abuse of alcohol and drugs, negative self-
esteem, negative expectations of other people, and a
greater risk of exposure to future potentially traumatic
events [16], it becomes clear that trauma exposure is as-
sociated with impairment and major health problems in
patients with psychosis, creating a burden for both pa-
tients and society [17,18].
Clinical attitudes and practice
In clinical practice, trauma exposure, PTSD and their links
to psychosis do not seem to get that much attention. Trau-
matic experiences and the diagnosis of PTSD appear to be
underreported in the charts of patients with a severe men-
tal illness or psychotic disorder [19,20]. In addition, clini-
cians are reluctant to address trauma histories in patients
with psychosis [21,22]. They will not easily offer therapy,
especially not exposure therapy, to overcome PTSD symp-
toms; instead, they suggest establishing trust and rapport
with patients first, and giving patients a sense of mastery,
before starting to explore traumatic experiences the pa-
tients might have had [23]. Many clinicians seem to fear
that trauma treatment with this patient group will lead to
symptom exacerbation, crisis, hospitalization, self-harm
and suicidal behavior, or rapid changes in medication. They
presume that before a PTSD treatment can be safely
conducted, stabilizing interventions are necessary [23,24].
Studies examining PTSD treatment efficacy
Meta-analytic studies of clinical trials show that, gener-
ally speaking, trauma focused cognitive behavioral ther-
apy (TF-CBT), such as prolonged exposure (PE), and eye
movement desensitization and reprocessing (EMDR) are
safe and effective. These treatments should be the first-
line psychological treatment for PTSD [25-27]. Unfor-
tunately, people with a psychotic disorder are often
excluded from PTSD treatment efficacy research [28,29].
Therefore, not much is known about the generalizability
of PE or EMDR efficacy to people with psychotic disor-
ders [30]. This question of applicability of PE and
EMDR in patients with psychosis is the starting point of
the present study protocol.
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A number of studies have already addressed this issue.
In a randomized controlled trial (RCT), the effects of
Cognitive Behavior Therapy (CBT) were investigated in
108 participants with severe mental illness, of which
14% (N =17) had a diagnosis of schizophrenic or
schizoaffective disorder [31]. The protocol consisted of
12 to 16 sessions of combined CBT interventions (a cri-
sis plan, psycho-education, breathing exercise, cognitive
restructuring). CBT proved to be effective in reducing
PTSD symptoms and was safe. In an open study, the ef-
fect of PE in people with psychosis was studied [32]. Par-
ticipants (N = 20) were given fourteen preparatory
sessions and eight PE sessions. The drop out was high
during preparatory sessions and this phase did not result
in a decline of symptoms. A high compliance, no adverse
events and a significant reduction of PTSD symptoms,
during and after PE, were, however, noted. These results
suggest that PE is effective and safe and preparation for
PE may be unnecessary.
Recently, our research group conducted two small feasi-
bility trials. The first, an open study (N = 27), used EMDR
for PTSD in people with a life time history of psychosis
[33]. The second study used EMDR (N = 5) and PE (N = 5)
in a multiple baseline controlled design [34]. Results
showed that both treatments were effective in reducing
PTSD symptoms. Van den Berg and Van der Gaag [33]
found significant reductions in end-state PTSD, symptom
severity of PTSD, delusions, hallucinations, depression
and anxiety and an increase in self-esteem. De Bont and
colleagues [34] found significant reductions of PTSD and
of general psychopathology and distress. In both studies
no serious adverse events or symptom exacerbations were
found. Both treatments were well accepted by participants
and attrition was low. Taken together, results from pilot
studies suggest that trauma-focused treatments, such as
PE and EMDR, can be effectively and safely applied to pa-
tients with psychotic disorders, but well-controlled studies
are lacking. To fill this gap, we set up the present study,
the Treating Trauma in Psychosis (T.TIP) study.
Objectives
Primary objective –effects of treatment on PTSD
symptoms and safety
In a sample of patients who receive treatment as usual
(TAU) for a current diagnosis of psychosis this study ex-
amines: a) the efficacy of PE versus waiting list, and of
EMDR versus waiting list, on the symptomatology of a co-
morbid PTSD; and b) the safety of PE versus waiting list
and EMDR versus waiting list in the treatment of PTSD.
Secondary objectives - effects of treatment on
psychopathology and cost effectiveness
Other objectives were to determine the efficacy of PE
versus waiting list and of EMDR versus waiting list on
the symptomatology of psychosis. In this context the ex-
perience sampling method (ESM) [35] will be applied to
examine the effects of treatment on temporal associations
between intrusions, daily events and activities, and verbal
hallucinations, depression,social functioning andpost trau-
matic cognitions.An economic evaluation will determine
the cost effectiveness of the PTSD treatments.
Tertiary objectives - links between trauma exposure,
PTSD and psychosis
An important objective is to assess, in the psychosis
sample, exposure to traumatic events, to assess and cal-
culate the risk of having a comorbid PTSD, and to diag-
nose comorbid PTSD. In this context, the diagnostic
accuracy of the Trauma Screening Questionnaire [36], in
the population of patients with psychotic disorder, will
be examined.
The present T.TIP study will address the question as
to whether certain types and severities of trauma expos-
ure are associated with specific phenomenological as-
pects of psychotic symptoms [7,8,37,38]. Specifically, the
study aims to explore the links between traumatic
events, PTSD and verbal hallucinations [12,33].
Quaternary objectives – mediators, moderators and
predictors of treatment outcome
In the intervention study we will conduct additional re-
search to explore mechanisms of changes in the treat-
ment outcome variables. Variables that are potential
predictors, mediators and moderators will be examined,
such as: a) bullying [7,8]; b) tonic immobility [39-41]; c)
the capacity of participants’ working memory [42,43]; d)
credibility of treatment and burden of treatment [44,45].
Both participants and therapists will have cognitions
about treatment that may affect treatment outcome.
Therefore assessments will be made of harm expectancy
and harm experience, expected burden and experienced
burden and credibility of treatment; e) demographic and
trauma characteristics; f ) self esteem [46-48]; g) personal
beliefs about illness [49,50]; h) post traumatic cognitions
[51]; i) cognitive biases [52-54]; j) cognitions about
voices; k) memory characteristics [55-58]; and l) social
support during treatment [59,60].
Methods/Design
Design
The T.TIP study is a single blind randomized controlled
trial with three arms: PE, EMDR and a waiting list. The
three groups are compared at pre-treatment (T0), at
post treatment at two months (T2) and at six months
(T6), on a set of variables that are linked to the various
research questions. Mediator and moderator variables
are assessed again at midtreatment (T1). A 12-month
treatment intervention follow-up measurement (T12)
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will give indications whether treatment effects endure.
The waiting list condition will receive the treatment of
choice after sixmonths (T6).
The assessing research assistants are blind to the partici-
pants’ research condition.
The design of this study was approved by the Medical
Ethics Committee of the medical centre of the VU University
and is registered as N:36649.029.12.
Participants
Patients, 18- to 65-years old, with a chart diagnosis of
psychotic disorder or a mood disorder with psychotic
features according to the Diagnostic and Statistical
Manual of Mental Disorders, fourth edition text revsion
(DSM-IV-TR) are recruited from outpatient services of
thirteen mental health organizations in the Netherlands.
The trial process starts with a short self-report screen-
ing. During the screening, participants report on trau-
matic events that fulfill DSM-IV-TR PTSD criterion A1
and associated PTSD symptoms using the 10 item
Trauma Screening Questionnaire (TSQ) [36]. If partici-
pants report traumatic events and score above the TSQ’s
cut-off criterion (x = ≥6), and give informed consent for
further interviewing, an appointment will be made for
the inclusion interview.
Inclusion and exclusion
The criteria for inclusion in the intervention study are:
a) age between 18 and 65 years; b) a lifetime history of a
psychotic disorder or a mood disorder with psychotic
features (M.I.N.I. plus); c) meeting DSM-IV-TR diagnos-
tic criteria for PTSD (Clinician Administered PTSD
Scale (CAPS)).
The criteria for exclusion are: a) high suicidality,
operationalized as the combination of having a high
suicidality score on the M.I.N.I. with the last suicide at-
tempt within the past six months and a depression score
on the Beck Depression Inventory-II (BDI-II) of 35 or
higher; b) changes in medication (mood regulators, anti-
psychotics) within two months prior to the study; c) in-
sufficient competence in the Dutch language; d) severe
intellectual impairment, defined as an estimated IQ
below 70 (mental retardation); e) not being able to travel
to and from the place of assessment and therapy; and f)
participant is in seclusion or admitted to a closed ward.
See Figure 1, the T.TIP flowchart. All mental health
teams that signed up for cooperation in the T.TIP study
carry out the standard procedure for screening of all
patients suffering from psychosis. After that, the flow of
consenting and screened participants into the study has
three pathways: (1) ‘regular’ inclusion, meaning that each
patient demonstrating a high risk for PTSD (TSQ ≥6) will
be invited for an inclusion interview; (2) ‘low TSQ’ inclu-
sion, meaning that a random sample of patients across the
teams (N = 200) demonstrating a low risk of having a
PTSD (TSQ ≤5) will be invited for a ‘low TSQ’-inclusion
interview; and (3) ‘incidental referrals’-inclusion.
The inclusion interview conducted by the research
assistant (RA) will be the same for all three categories
‘regular’, ‘low TSQ’ and ‘incidental referrals’: (a) three sec-
tions of the M.I.N.I.-Plus interview for assessing psychotic
disorders, mood disorders with psychotic features and a
risk analysis regarding acute suicidality; (b) the CAPS [61]
for assessing a PTSD diagnosis; and (c) the BDI-II [62] for
assessing the severity of depressive symptoms.
‘Regular’ participants who meet the inclusion criteria
and give consent go to the randomization phase. ‘Low
TSQ’-participants who appear to meet all criteria for
inclusion (including a PTSD despite their low TSQ
screening score) may also enter the randomization phase.
The third group is that of incidental ‘referrals’. Referred
participants will not be recruited using the standard
screening procedures in cooperating teams. Instead,
psychiatrists, psychotherapists, caseworkers or patients
from other teams will be offered the opportunity to refer
for screening and possible entry in the intervention study.
They may do so, if thereare indications the patient may
have psychosis and PTSD and may benefit from participa-
tion. The diagnostic data of referred participants will be
excluded from some of the study’s analyses, but these will
be part of all treatment outcome analyses.
Randomization
All patients meeting the inclusion criteria are asked for
written informed consent to participate in the intervention
study. Consenting participants receive the pre-treatment
(T0) measurements. (Note that for patients with auditory
hallucinations six days of T0 measurements on auditory
verbal hallucinations are added, using ESM; see Instru-
ments). After T0, participants are randomized to PE,
EMDR or the waiting list. A group of fifteen random
assignments for each participating therapist will be made.
These groups are made using the scientific randomization
program on the Internet (www.randomizer.org) by the
independent randomization bureau of the Parnassia
Psychiatric Institute. Each block has five assignments for
each condition: PE or EMDR or waiting list. Thus, each
therapist treats five people with PE and five people with
EMDR. After six months, the therapist will offer the five
people from the waiting list the therapy of their choice.
Power and sample size calculation
An F-test over three groups with a medium effect-size of
treatment compared to waiting list, alpha .05 and power
.80 needs 159 participants. Attrition is estimated conser-
vatively to be high at 33%. The needed number of partic-
ipants is 240. We will use 3 x 80 participants.
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To minimize missing values: (a) research assistants will
use letters, text messages, telephone calls, and contacts with
participants' case workers for inviting participants and for
reminding them about their assessment appointments; (b)
therapists are reminded by mail and in supervision to con-
duct their assessments, be it assessments within sessions or
at T1, T2 and T6; and (c) therapists are encouraged by mail
to remind and support the participant to go to the assess-
ment appointments with the RA at T2, T6 and T12.
All the participants will receive financial compensation of
twenty-five euros for every single measurement at T0, T2,
T6 and T12, regardless of whether or not the participant
drops out of treatment. The compensation will be paid at
the planned end of participation (T6 for waiting list partici-
pants, T12 for participants in the treatment condition).
Interventions
Treatment as usual (TAU)
Participants in all three conditions PE, EMDR and waiting
list receive TAU, consisting of antipsychotic medication,
and treatment and/or supportive counseling by therapists,
caseworkers or coaches (for example, Individual Placement
and Support). TAU is considered to be equal in the three
conditions as a result of the randomization procedure used
(see Randomization).
Prolonged exposure (PE)
PE therapy is a psychotherapeutic approach that reduces
PTSD symptom-severity by systematically exposing the
subject,in both imaginary and in vivo ways, to previously
avoided traumatic internal and external stimuli. [63].
Thetrauma-related fear memory network is activated by PE
and psychopathological cognitions may be changed during
PE [64]. PE consists of eight sessions of 90 minutes.
In the first treatment session, a case conceptualization is
made in order to plan the treatment sessions. The therapist
receives information from the Interview for Traumatic
Events in Childhood (ITEC) [65], an interview that is part
of T0. The ITEC captures categories (for example, sexual
abuse, physical abuse) of experienced traumatic events. In
addition, the intensity of re-experiencing symptoms of
each traumatic event is assessed. Based on the ITEC, the
therapist draws up a preliminary, formatted PE case
conceptualization. In the first treatment session, the
Screening for PTSD (regular procedure)
High risk for PTSD & consent Low risk for PTSD & consent
Random selection (N = 200)
Inclusion interview Inclusion interview
Screening & 
consent
Prolonged Exposure
Allocation
Follow-Up
Enrollment
Referrals
Inclusion
Exclusion | Inclusion Exclusion | Inclusion Exclusion | Inclusion
Randomisation
EMDR Waiting list
T0
T1
T2
T1
T6
T2
T6T6
Treatment of choiceT12T12
Patients with psychosis
Figure 1 Flow Diagram T.TIP.
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therapist will discuss and complete the case concep-
tualization together with the patient. This results in a hier-
archy of the most relevant traumatic memories in order of
significance with regard to the symptoms of PTSD. A
highly qualified supervisor (AvM) reviews each case
conceptualization.
In the first session, the therapist will explain the treat-
ment rationale to the participant. Imaginary PE is carried
out from the second treatment session: the confronta-
tion with avoided anxiety provoking memories, during
45 to 60 minutes per session. The participant imaginarily
relives the traumatic events. The therapist prompts the
participant to tell details about the memory and to relive
the memories very vividly, as if it was happening here
and now. The participant is instructed to reveal sensory
details of the traumatic events, and to talk in the present
tense and from a personal first person perspective. The
therapist helps the participant to expose himself or her-
self to the most fearful parts of the memory, the so-
called hot spots. Subjective Units of Distress (SUDs,
range 0 to 100) reflecting the levels of distress are moni-
tored during the PE sessions. Each session is recorded and
stored with a voice recorder. At home the participant lis-
tens to the complete recording five days a week, scoring
the SUDs prior to, during and after listening. At session
three exposure in vivo is added. A list is made of avoided
trauma related stimuli. As homework, the participant sets
out to confront these situations in vivo (including: on the
internet). Again distress levels (SUDs) prior to, during,
and after in vivo exposure are monitored.
Eye movement desensitization and reprocessing (EMDR)
EMDR is a psychotherapeutic approach, in which memory
representations of traumatic life experiences are processed
in order to change dysfunctional beliefs about self or others
that originated from damaging traumatic experiences
[66,67]. EMDR consist of eight sessions of 90 minutes.
As in PE, in the first treatment session a case concep-
tualization is made in order to plan the treatment ses-
sions. The therapist receives information from the ITEC.
The ITEC captures categories (for example, sexual
abuse, physical abuse) of experienced traumatic events.
In addition, the intensity of re-experiencing symptoms
of each traumatic event is assessed. Based on the ITEC,
the therapist draws up a preliminary, formatted EMDR
case conceptualization. In the first treatment session, the
therapist will discuss and complete the case concep-
tualization together with the patient. This results in a
hierarchy of the most relevant traumatic memories in
order of significance with regard to the symptoms of
PTSD. A highly qualified supervisor (CdR) reviews each
case conceptualization.
After acceptance, memories are subsequently processed
following the Dutch translation [68,69] of the basic EMDR
protocol [67]. The participant is asked to focus on the
currently most distressing image of a memory in a multi-
modal manner, including image, thought (an experienced
negative cognition (NC) and a more healthy positive
cognition (PC)), emotion, physical sensation and level of
tension (SUD). Processing of the memory starts when the
therapist asks the patient to hold the target image in mind
while concentrating on a distracting stimulus (the finger
of the therapist eliciting eye movements) for about 30 sec-
onds. The patient reports briefly what comes to mind and
is guided by the clinician to refocus on that element while
focusing on the distracting stimulus. This continues until
no more associations come up and the disturbance level
associated with the target memory (SUD) drops to zero.
Then the therapist guides the participant in installing the
PC to a maximum validity, that is a Validity of Cognition
(VOC) score seven. The participant identifies any residual
disturbing sensations and, if present, the memory will be
processed again in the same manner as described above,
until the SUD is zero and the VOC PC is seven. The ther-
apist facilitates a positive closure to the session. In the
next session a re-evaluation takes place in which the par-
ticipant comments on previously processed targets as a
basis for further intervention.
Early completions
A participant will be considered an early completer of
treatment when (a) his or her score on the PTSD Symp-
toms Scale – Self Report (PSS-SR) is lower than 10 on
two consecutive occasions, and if (b) the SUDs from all
situations that are part of the case conceptualization are
reduced to zero.
Measurements
Subjects participate in the study for 12 months. At T0,
the RA assesses baseline measurements of all primary,
secondary, tertiary and quaternary variables. At T1, at
midtreatment, participants in treatment conditions are
assessed for their scores on the moderator and mediator
variables by self-report questionnaires handed out by the
therapist. At T2, the end of treatment, the RA assesses
treatment outcome variables. T6 is the first follow-up
measurement, and this is the starting point for treatment
for the waiting list group. T12 is the 12-month follow up
measurement for the PE and EMDR group.
For participants in the treatment conditions PE and
EMDR some assessments are planned within sessions:
PTSD symptom severity, therapy burden, harm expect-
ancy (pre-session) and experienced harm (post-session),
adverse events (pre- and post-session), credibility of treat-
ment and memory characteristics. Note that therapists are
also assessed independently from the participants for per-
ceived and experienced treatment burden credibility and
harm, before, during and after treatment.
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Instruments
Measurements – inclusion
The M.I.N.I.-International Neuropsychiatric Interview-
Plus (M.I.N.I.-Plus) [70-72] is used as an inclusion tool.
The M.I.N.I.-Plus sections for psychotic and mood disor-
ders will be used to assess lifetime psychotic disorder or
mood disorder with psychotic features at recruitment.
The M.I.N.I.-Plus is a short diagnostic interview sched-
ule that can be easily incorporated into routine clinical
interviews and is well accepted by patients [73]. The M.
I.N.I.-Plus may be used in research [74]; it is fit to clas-
sify psychotic and mood disorders [74,75]. According to
the C.I.D.I. [70] the Kappa coefficient, sensitivity and
specificity of the M.I.N.I. were good (>0.70) or very good
(>0.80) for most diagnoses including psychotic and
mood disorders. Inter-rater and test-retest reliability
were good (>0.70). Validation against the Structured
Clinical Interview for DSM-IV (SCID-P) supported the
validity and reliability of the M.I.N.I. [71].
As pointed out in the section Inclusion, the original
M.I.N.I. module of suicidality was used as part of the al-
gorithm used to exclude patients.
Measurements –effects of treatment on PTSD symptoms
and safety
See Table 1, Primary outcome measurements.
The CAPS [61] is the primary outcome measure. The
CAPS assesses the presence or absence of PTSD diagno-
sis and the frequency and intensity of the clinician's
rated PTSD symptoms. The CAPS provides ratings of
the frequency and intensity of each of the 17 DSM-IV–
TR based PTSD symptoms on 0 to 4 Likert-type scales,
thereby allowing for a maximal score of 8 for each
symptom and a total-score range from 0 to 136. The
CAPS is considered the gold standard to diagnose
posttraumatic stress disorder as defined in the DSM-IV
-TR and to establish its severity. A review of the empir-
ical literature on psychometric properties of the CAPS
[76] indicates that the CAPS has excellent reliability
(>0.90), yielding consistent scores across items, raters
and testing occasions. There is also strong evidence of
validity: the CAPS has excellent (>0.90) convergent and
discriminant validity, diagnostic utility, and sensitivity to
clinical change.
The Posttraumatic Stress Symptom Scale, Self-Report
(PSS-SR) [77] is administered to assess self-reported
severity of PTSD symptoms [78]. The PSS-SR consists of
17 items corresponding to the 17 diagnostic DSM-IV-TR
criteria of PTSD which are rated on a 3-point Likert
scale, where 0 = not at all, 1 = a little bit, 2 = somewhat
and 3 = very much. It yields a total score measuring
symptom severity (range 0 to 51), as well as separate se-
verity scores for re-experiencing (range 0 to 15), avoid-
ance (range 0 to 21), and arousal (range 0 to 15). The
PSS-SR is assessed before each treatment session, to
assess changes in the PTSD symptoms during treatment.
There is a satisfactory internal consistency (Cronbach’s
alpha = 0.91), high test–retest reliability (r = 0.74) and
good concurrent validity (sensitivity = 62%, positive pre-
dictive power = 100%, negative predictive power = 82%
[77,79]. In a sample of patients with a first-episode
psychosis the screening performance of the PSS-SR was
tested against CAPS interview results [80]. The data sug-
gest that the PSS-SR can be a useful screening instru-
ment for PTSD in this group of patients. Sensitivity was
0.83 and specificity was 0.83.
The T.TIP Adverse Events Questionnaire (T-AEQ) is a
checklist that establishes treatment safety. In seven ques-
tions the patient is asked to report any self-inflicted pain
or injury, suicide attempt, deliberately hurting or physic-
ally wounding another person, excessive use of alcohol,
excessive use of drugs, having needed help because of a
crisis and being admitted to a psychiatric hospital. The
time frame is two months.
The Adverse Events session ratings assesses adverse
events in the participant before and after treatment ses-
sions (sessions two and three), for example, being suicidal,
hearing voices. Participants respond on a 10-point visual
analog scale (VAS;‘no, not at all’ to ‘yes, very much’) to the
questions.
Measurements – effects of treatment on psychopathology
and cost effectiveness
See Table 2, Secondary outcome measurements.
The Green Paranoid Thought Scales (GPTS) [81] is a
self-report measure that assesses changes in paranoid
experiences and in ideas of reference. It consists of 32
statements about experiences in the last month, sixteen
Table 1 Measurements primary objectives: PTSD and safety of treatment
Primary
outcome
MeasurementInterview(i),
self-report(s)
T0
baseline
T1
midtreatment
Within-session
(1–8)
T2
posttreatment
T6 FU 6
months
T12 FU 12
months
PTSD CAPS (i) x x x x
PSS-SR (s) x 1, 2, 3, 4, 5, 6, 7, 8 x x x
Adverse events TAEQ (s) x x x x x
AE session ratings (s) 2 ,3
AE adverse events, CAPS Clinician Administered Post traumatic stress disorder Scale, FU follow up, PSS-SR Posttraumatic Stress Disorder Symptom Scale - Self
Report, TAEQ T.TIP Adverse Events Questionnaire.
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items about ideas of persecution and sixteen items about
ideas of reference. Items are scored on a Likert scale
ranging from 1 (not at all) to 5 (totally). The range of
the total score is 32 to 160, with higher scores indicating
higher levels of paranoia. The GPTS has good internal
consistency, is valid, reliable and sensitive to clinical
change [81].
The Auditory Hallucination Rating Scale (AHRS), which
is part of the Psychotic Symptom Rating Scale(PSYRATS)
[82], is an eleven questions interview that assesses the se-
verity of auditory hallucinations: their frequency, duration,
location, loudness, causal attribution, negative content, the
severity of negative content, the extent and the severity of
discomfort and suffering, the disruption of daily life because
of voice hearing and the experience of control over voices.
Scores are on a range from 0 (for example,‘not’) to 5
(for example,‘continuously’). The range of the total score is
11 to 55. The inter-rater reliability is excellent (.79 to 1.00).
The Delusion Rating Scale (DRS) is part the Psychotic
Symptom Rating Scale (PSYRATS) [82]. It assesses the
severity of delusions. Six questions go into the extent
and the duration of preoccupation with the delusion, the
credibility, the extent and severity of discomfort and
suffering, and the disruption of daily life because of the
delusions. Items are scored from 0 (for example, ‘not’) to
5 (for example,‘continuously’). Total score ranges from 0
to 30. Inter-rater reliability is excellent (.79 to 1.00).
The ESM is an assessment technique designed to obtain
repeated self-reports, using an electronic beeper that
signals subjects to fill in a questionnaire at preselected but
randomized time points for several days [83]. In T.TIP the
effect of treatment on auditory (verbal) hallucinations is
studied. Therefore, only participants that experience ver-
bal hallucinations every day may participate. Participants
who will be part of this ESM study carry a palmtop-like
device called a Psymate[84], programmed to beep 10 times
a day for six consecutive days at T0 and T6. The question-
naire consists of 50 self-exploratory questions used in
previous studies, beginning with the most transient experi-
ences (mood, thoughts and symptoms), followed by more
stable items (context) and retrospective items in last po-
sition. All items are scored on Likert scales (range 1 to 7)
or category boxes.
ESM has been proven to be a valid, reliable and feasible
method of investigating psychotic experiences [35,85] by
the use of face validity, comparison of aggregated data
between groups, correlations between similar and dissimi-
lar items and determining associations with available
behavioral/external referents. ESM is useful for refining
the phenomenology of psychotic symptoms, for investiga-
ting etiological mechanisms underlying psychosis and in
clinical practice [86,87].
The Beck Depression Inventory second edition (BDI-II)
[88] is a self-report that consists of twenty-one items. Each
item is rated on a 4-point Likert-type scale ranging from 0
to 3, with higher scores indicating higher levels of depres-
sion. The measure asks respondents to rate statements
characterizing how they have been feeling throughout the
past two weeks. The maximum total score for all 21 items
is 63. Score categories range from 0 to 13 (minimal
depression), 14 to 19 (mild depression), 20 to 28 (mode-
rate depression) and 29 to 63 (severe depression). Good
psychometric properties have been shown for the original
BDI [89] and for the 1996 revision BDI-II [88] that is
adapted to depression criteria in the DSM-IV. The BDI-II
shows good validity compared to the Hamilton Depression
Rating Scale (Pearson r of 0.71). The test has high internal
consistency (α=.91) [62].
Table 2 Measurements secondary objectives: psychopathology and cost effectiveness
Secondary outcome MeasurementInterview(i),
self-report(s)
T0 baseline T1 midtreatment T2 posttreatment T6 FU 6 month T12 FU 12 months
Paranoid thinking GPTS (s) x x x x
Verbal hallucinations AHRS (i) x x x x
Delusions DRS (i) x x x x
Basic assumptions AVH-BAS (s) x x x x x
Verbal hallucinations ESM (s, psymate) x x
Depression BDI-II (s) x x x x
Social functioning PSP (i) x x x x
Posttrauma cognitions PTCI (s) x x x x x
Remission SCI-SR (i) x x x x
Care consumption TiC-P (s) x x x x
Health outcome EQ-5D (s) x x x x
AHRS Auditory Hallucination Rating Scale, AVH-BAS Auditory Verbal Hallucinations – Basic Assumptions Scale, BDI-II Beck Depression Inventory - II, DRS Delusion
Rating Scale, ESM Experience Sampling Method, EQ-5D™ EuroQol - 5 dimensions GPTS Green ParanoiaThought Scale, PSP Social Performance Scale PTCI
Posttraumatic Cognitions Inventory, SCI-SR Structured Clinical Interview for Symptoms of Remission for the PANSS, TiC-P Trimbos/iMTA questionnaire for Costs
associated with Psychiatric Illness - short version.
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The Personal and Social Performance Scale (PSP) [90]
assesses social functioning as a secondary treatment out-
come measure. The PSP scale is a clinician-rated scale
that measures personal and social functioning in the do-
mains of socially useful activities (for example, work and
study), personal and social relationships, self-care, and
disturbing and aggressive behaviors. Difficulty in each
area is rated according to set criteria, using a six-point
scale: absent, mild, manifest but not marked, marked, se-
vere, and very severe. On the basis of the subscale rat-
ings, a global score is rated by the interviewer, ranging
from 1 to 100 in ten point intervals, where lower scores
indicate lower functioning.
The PSP was shown to be able to detect changes in
patients with both stable and acute psychotic disorders
[91]. The PSP has been developed through focus groups
and reliability studies on the basis of the social function-
ing component of the DSM-IV-TR Social and Occupa-
tional Functioning Assessment Scale (SOFAS). The PSP
showed good (>0.80) interrater reliability and test–retest
reliability [90-92].
The Posttraumatic Cognitions Inventory (PTCI) [93]
assesses cognitions after having experienced a trauma.
Note that the PTCI will be mentioned again in the sec-
tion on ‘Tertiary measurements: predictors, moderators
and mediators of treatment outcome’. The PTCI serves
two goals: (a) post traumatic cognitions may be altered
as a consequence of treatment; and (b) post traumatic
cognitions may function as a predictor variable of treat-
ment outcome. The PTCI consists of 33 items and three
subscales. Negative Cognitions About Self (general nega-
tive view of self, permanent change, alienation, hopeless-
ness, self-trust and negative interpretation of symptoms)
contains 21 items). Seven items represent the second
factor of Negative Cognitions About the World (unsafe
world and mistrust of other people). Five items represent
the third factor of Self-Blame. Participants rate each
item on a 7-point Likert-type scale, from 1 (totally dis-
agree) to 7 (totally agree). Thus, high scale scores indi-
cate stronger maladaptive cognitions. The scores of the
three factors are calculated by dividing the sum score by
the number of items (factor scores range from 0 to 7).
The total score is the sum of the three factor scores
(maximum of 21). Internal consistencies of the three
subscales were found to be excellent (0.86 to 0.97). The
test-retest reliability was good (0.74 to 0.86). The PTCI
was shown to discriminate better between individuals
with and without PTSD (86% classified correctly) than
other tools for assessing trauma-related cognitions [93].
Sensitivity and specificity were proven good [94].
The Structured Clinical Interview for Symptoms of Re-
mission for the PANSS (SCI-SR, eight items) [95] is a
brief eight-item interview that is used in research and
treatment settings to assess remission of psychotic
symptoms, based on eight items of the Positive And
Negative Syndrome Scale (PANSS) [96]. In the present
study it is part of the research of economic costs. The
participant has to confirm functional status on four
items: delusions, unusual content of thought, hallucina-
tions and apathy. Scores on the other four items are
based on observation and participants’ responses: con-
ceptual disorganization, lack of spontaneity, blunted
affect and posturing. Each item is rated using criteria de-
scribed in the PANSS Manual. The PANSS determines
severity of symptoms on 7-point Likert scales. Remission
on the PANSS-SCI-SR is defined as a score of three
(mild) or less for each item, maintained over a six-
month period [97]. Compared to the total PANSS score
the specificity of the remission criteria was 85%. The
sensitivity was 75%. The remission criteria are both sen-
sitive and specific indicators of clinical status. Additional
analyses are required to determine if remission status
predicts other outcomes, such as employment, inde-
pendent living, and prognosis [98].
The Trimbos/iMTA questionnaire for Costs associated
with Psychiatric Illness (TiC-P, short version) [99] will
be used to assess the costs. Trimbos and the Institute
for Medical Technology Assessment (MTA) developed
this care consumption list. The TiC-P is commonly ap-
plied in the economic evaluation of treatment in mental
health care, including trials on the cost utility of brief
psychological treatment for anxiety (for example, see
[98,100]. To be able to calculate the total direct medical
costs, the first part of the Tic-P assesses the total num-
ber of medical contacts (outpatient visits, length of stay
in hospital, use of medication, and so on). Afterwards,
the data will be multiplied by unit costs of the corre-
sponding health care services. Reference unit prices of
health care services will be applied and adjusted to the
year of this study according to the consumer price index.
In the second part of the TiC-P a short form of the
Health and Labor questionnaire (HLQ) [101] will be
used to collect data on productivity losses. The Short-
Form HLQ (SF-HLQ) consists of three modules that
measure productivity losses: absence from work, reduced
efficiency at work and difficulties with job performance.
The EuroQol (EQ-5D™) [102,103] is a standardized in-
strument for measuring health outcome. This patient-
reported outcome measure has five dimensions: mobility,
self-care, usual activities, pain/discomfort and anxiety/de-
pression, and each dimension has three levels (no prob-
lem, some problem, severe problem). Together, these five
dimensions make a simple descriptive profile that can be
compared to a total of 243 health states scored using
values obtained from a survey of the general population.
Participants also point out a single index value for current
health status on a scale from 0 (‘worst possible health’) to
100 (‘best possible health’). The EQ-5D measures and
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expresses quality of life in utilities. Utilities can be com-
bined with cost-effectiveness data into Quality Adjusted
Life Years (QALYs). The EQ-5D has good reliability and
validity [103].
Measurements – links between trauma exposure, PTSD
and psychosis
See Table 3, Tertiary outcome measurements. Note that
the measurements of psychosis mentioned in Table 2 are
necessary, too, for examination of the tertiary objectives.
T.TIP screener, including the TSQ. The T.TIP screener
is designed for the purpose of briefly asking: a) about
having experienced overwhelming or life threatening ex-
periences (‘yes’ or ‘no’); and b) If ‘yes’, then participants
are asked what kind of PTSD DSM-IV-TR criterion A
traumatic events they have experienced: physical abuse,
sexual abuse, emotional abuse, extreme neglect and/or
accidents/disasters/war. Because patients in this specific
patient population may also have experienced traumatic
events during psychotic episodes, this category was
added. For each category of traumatic events the partici-
pant chooses between ‘yes, one traumatic experience’,
‘yes, more than one traumatic experience’ or ‘no trau-
matic experience’. c) To gain more information about
the phenomenological similarities between trauma con-
tent and content of the symptoms of their psychosis,
participants are asked about similarities (‘no similarity at
all’, ‘some similarity’ or ‘strong similarity’). d) Participants
then answer questions about PTSD symptoms they may
suffer, using the TSQ [36]. The TSQ is a 10-item scale
with the five re-experiencing items and five hyperarousal
items of the PSS-SR. All items are answered with binary
‘yes' (symptom is present two times a week or more) or
'no’ (symptom is not present or present once a week)
responses; the minimum score is zero and the maximum
score is ten. The TSQ has a good sensitivity in assessing
potential PTSD in crime victims (0.76) and rail crash
victims (0.86), as well as a high specificity in both of
these groups (0.93 and 0.97, respectively) [36]. The TSQ
has also shown to be a good measure to predict future
PTSD in assault victims, with a sensitivity of 0.85, a spe-
cificity of 0.89, and an efficiency of 0.90 [104]. Both
studies mentioned above [36,104] calculated that the
optimum cut-off score is 6; any combination of six or
more re-experiencing or hyper arousal symptoms pre-
dicts PTSD best. The TSQ is not yet calibrated for
people with psychotic disorders.
The Inventory of Traumatic Events in Childhood (ITEC)
[65] is used to interview the participant for traumatic
events in his or her life. The ITEC consists of five subcat-
egories: sexual abuse, physical abuse, emotional or psycho-
logical abuse, emotional and physical neglect, and ‘other
traumas’ that include items such as disaster, war, acci-
dents, illness and death of loved ones. Within each cat-
egory (for example, physical abuse) a number of specific
events are presented (for example,‘You were beaten or got
punched’). The participant has to respond to several ques-
tions: ‘Did this ever happen to you? ‘, ‘Who did this to
you?’, ‘How old were you when this happened?’, ‘Did this
occur once, or more?’
For the purpose of the study (a) a category of traumatic
events during psychotic episodes was added. This category
includes specific events such as ‘A psychosis in which you
hurt yourself or tried to kill yourself ’; ‘a psychosis in which
you were locked up or tied up against your will?’; and b)
an assessment was added of both intensity (SUD) and fre-
quency of intrusions for each reported traumatic event.
The psychometric properties are good [65]. The scales had
good internal consistency (>0.70), except for the physical
neglect subscale and an excellent (>0.90) inter-rater reli-
ability. The scales were highly associated with equivalent
scales of the Childhood Trauma Questionnaire (CTQ)
(that is, good convergent validity) and showed good cor-
respondence with patient file information (that is, good
criterion validity). Internal reliability of the ITEC subscales
range from .58 to .89 with a mean of .79. The reliability
for the physical neglect scale is inadequate, while the other
scales display moderate to good reliability. Results showed
excellent agreement between the raters for most subscales
(intraclass correlation coefficient (ICC) sexual and physical
abuse = 1.00; ICC emotional abuse and neglect = .99; ICC
witnessing physical abuse = .88; ICC witnessing emotional
abuse = .96) and good agreement for the physical neglect
scale (ICC = .72). Additionally, high correlations with the
corresponding subscales of the CTQ [105-107] were
obtained, indicating good convergent validity. Finally, cri-
terion validity was assessed by comparing the presence of
maltreatment as mapped by the ITEC with patient file in-
formation. Data indicated that the ITEC's sensitivity was
excellent, and their scores on their parallel ITEC subscales
uniquely predicted sexual and physical abuse and neglect.
This was not the case for emotional abuse.
Measurement – moderators, mediators and predictors of
treatment outcome
See Table 4, Quaternary measurements. Note that only
measurements on participant variables are included.
Table 3 Measurements tertiary objectives: links between
trauma exposure, PTSD and psychosis
Tertiary outcome MeasurementInterview(i)
self-report(s)
Screening T0 baseline
Trauma categories;
PTSD risk
T.TIP screener /TSQ (s) x
Traumatic events ITEC (i) x
ITEC Interview for Traumatic Events in Childhood, T.TIP screening/TSQ TTIP
screening including the Trauma Screening Questionnaire.
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Look at the therapist ratings section for explanation of
measurements of therapist variables.
The Bullying Questionnaire (BQ) [108,109] is used to
collect information about being severely bullied in child-
hood (age <17) as a predictor variable of treatment out-
come. The BQ is derived from the original Olweus Bully/
Victim list, which has 40 items. The BQ has five items.
The BQ questions have been used in the European net-
work of national schizophrenia networks studying Gene-
Environment Interactions (EU-GEI). The BQ questions
are taken from the Environmental Risk (E-Risk) longitu-
dinal twin study which they adapted from Olweus and
have used in several publications, showing good test-retest
reliability [108] and reasonable inter-raterreliability [110].
Participants answer if they have been bullied by other
children, if they have been physically hurt or injured by
other children, if they have been hurt emotionally or psy-
chologically, how severe the bullying was, and if they ever
have bullied other children themselves. Scores are on a
range from zero (‘never’ or ‘not’) to four (‘often’ or ‘severe’)
and total scores of the BQ thus range from 0 to 20.
The Tonic Immobility Scale–Adult Form, Part 1- Short
Version(TIS-A-1-SF) [111]) is used to study tonic immo-
bility as a predictor of treatment outcome. TI as a reaction
to a traumatic event is originally found mostly in sexually
abused women [112] but is also known to occur during
other traumatic events. The original TIS-A-Part 1 ad-
dresses symptoms of tonic immobility and peritraumatic
fear and perceived inescapability [113]. Thus, this TIS-A
-Part 1 score represents the individual’s experience of vari-
ous aspects of the TI response during the traumatic event.
The TIS-A-Part 1-Short Form specifically addresses TI. It
consists of four items, assessing four possible responses
during the traumatic event: (1) freezing, (2) immobility,
(3) not being able to shout or scream and (4) possibility of
escaping the situation. Answers are on a 7-point Likert-
type scale (0 to 6). Psychometric properties of the original
TIS-A scale [113] were good, but no data are available
with regard to the short version used in the T.TIP study.
The auditory Random Interval Repetition (RIR) task is a
computerized reaction time task, that is studied as a pos-
sible predictor and moderator of treatment outcome. Dur-
ing this task participants wear headphones that present
repetitive beeps of 200 Hz, each lasting for 50 ms. The
inter-stimulus-interval (ISI) on this computerized RIR task
is either 850 or 1450 ms. Participants are instructed to re-
spond as fast as possible by pressing a bar, every time they
hear a beep, and the reaction time (RT) is the dependent
variable. The RIR task is carried out under two conditions
of three minutes each: 1) while making a distracting task,
in this case eye movements, elicited by the index-finger of
the research assistant, moving horizontally at 30 cm from
the eyes at a pace of two seconds per cycle, and 2) without
a distracting task. The order of the conditions is coun-
terbalanced to control for carry over effects. The degree to
which eye movements tax the central executive compo-
nent of the working memory is operationalized as the
slowing down of RTs and reduced accuracy (more errors
and non-responses) during the distracting task compared
with the no-distracting task condition. The task is
constructed and performances measured with E-Prime 1.2
software.
Table 4 Measurements quaternary objectives: predictors, moderators, mediators (participant variables)
Quaternary outcome MeasurementInterview(i)
self-report(s)
T0 baseline T1 midtreatment Within-session
(1 to 8)
T2 posttreatment T6 FU 6
month
T12 FU 12
months
Bullying BQ (s) x
Tonic immobility TIS-A-1-SF (s) x
Working memory RIR x
Credibility participant CS-PF (s) 1, 8
Burden participant BS-PF (s) 1, 8
Harm expectancy pre session rating (s) 2, 3
Harm experience post session rating (s) 2, 3
Demographics TDQ x
Self esteem SERS-SF (s) x x x
Illness beliefs PBIQ (s) x x x
Post trauma cognitions PTCI (s) x x x x x
Cognitive bias DACOBS (s) x x x
Memory MCQ-RF (s) 2, 3, 8
Social support MOS-SSS (s) x
AVH-BAS Auditory Verbal Hallucinations Basic Assumptions Scale, BQ Bullying Questionnaire, BS-PF Burden Scale – Participant Form, DACOBS Davos Assessment of
Cognitive Biases Scale, FU follow up, MCQ-RF Memory Characteristics Questionnaire – Revised Form (adapted for T.TIP), MOS-SSS Medical Outcome Studies - Social
Support Survey, PBIQ Personal Beliefs about Illness Questionnaire – Revised version, PTCL Posttraumatic Cognitions Inventory, RIR Random Interval Repetition,
SERS-SF Self Esteem Rating Scale - Short Form, TDQ T.TIP demographic questionnaire, TIS-A-1-SF Tonic Immobility Scale- Adult Form-Part 1-Short Form.
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To have a RT task carried out while the subject is be-
ing distracted simultaneously, is a valid way to assess the
presence and severity of cognitive taxing [114]. RTs to
auditory cues presented at an RIR task, provide a valid
and highly sensitive measure of taxation of the central
executive component of the working memory [115]. La-
boratory experiments with undergraduates have shown
that 1) making eye movements during a stimulus dis-
crimination task slows down RTs and raises the number
of errors made [116] and 2) more taxing of the working
memory results in higher RTs, more errors and more
non-responses [117]. In a pilot study with 12 patients
with a psychotic disorder we found the same patterns in
the performance on the RIR task with three conditions:
no eye movements, eye movements at one second per
cycle and eye movements at two seconds per cycle (pub-
lication in preparation). In T.TIP two seconds per cycle
will be used.
Several measures of treatment credibility, burden,
harm expectancy and harm experience are administered
to both therapists and participants.
First, the T.TIP Therapist attitude questionnaire (T-
TAQ) aims to measure therapist attitude towards the
treatments (PE and EMDR). This has two goals: (i) to
study therapist treatment attitude as a predictor variable
on treatment outcome, and (ii) to study the impact of
training and experience on therapist treatment attitude.
The T-TAQ is repeatedly administered in the context of
training and supervision sessions. The T-TAQ consists
of 15 items, divided into three parts a, b (with within
session extension) and c (with within session extension).
(a) The Impact of Training and Therapeutic Experience
Questionnaire – therapist form (ITTEQ-TF) assesses the
therapist factor of ‘Training and therapeutic experience’
in PE and EMDR. In this three item therapist self-report
list, therapists disclose on a 1 (‘totally disagree’) to 10
(‘totally agree’) VAS their level of (1) training in EMDR/
PE, (2) experience in carrying out EMDR/PE and (3) the
number of patients treated successfully using EMDR/PE.
(b-1)The Credibility Scale- therapist form (CS-TF).
Therapists respond to five treatment credibility state-
ments regarding PE and EMDR on a 1 to 10 VAS: (1)
This treatment seems logical to me. (2) This treatment
seems scientific to me. (3) If I have a PTSD, I would
choose this treatment. (4) This treatment would be ef-
fective for most people. (5) If a close friend or relative
has PTSD, I would recommend this therapy to them.
The CS-TF is an adaptation of the original Credibility/
Expectancy Questionnaire [118] which demonstrated
high internal consistency within each factor (credibility
and expectancy) and good test–retest reliability. (b-2)
The Credibility Scale- therapist session form (CS-TSF) is
an adaptation of the CS-TF. It is an extra 10-item cred-
ibility rating that will be applied within actual treatment
sessions (1 and 8); the therapist rates not only his or her
own opinions on credibility, but in addition makes an
estimation of how he or she expects the participant to
rate the credibility of the treatment on the same five
questions of the CS-TF ('logical' and so on). (c-1)The
Burden Scale-therapist form (BS-TF). Seven questions
regarding PE and EMDR assess ‘Perceived barriers’ on a
1 to 10 VAS: (1) PTSD will get worse, (2) psychosis will
get worse, (3) other comorbid symptoms will get worse,
(4) the treatment is a burden to the patient, (5) the treat-
ment is a burden to the therapist, (6) the treatment will
facilitate drop out, (7) the treatment will facilitate crisis
or admissions to hospital. The BS-TF is inspired by
studies that compare the burden and endorsement of
CBT and EMDR (for example, studies using the Distress/
Endorsement Validation Scale (DEVS)) [119,120]. The
BS-TF is not an adaptation of the DEVS, however. It is
adapted to suit the research questions of the study regard-
ing (perceived) barriers for treatment in the population of
patients with psychosis. There are no psychometric evalu-
ations available. (c-2) The Burden Scale- therapist session
form (BS-TSF) is an adaptation of the BS-TF. It is an extra
three-item burden rating that will be applied within actual
treatment sessions (1 and 8); the content is limited to esti-
mations by the therapist of how he or she expects the par-
ticipant to rate the burden of the treatment on a 1 to 10
VAS (‘no, not at all’ to ‘yes, very much’): (1) Does the par-
ticipant fear treatment?, (2) Is he or she hesitant to have
this treatment?, and (3; only for PE) Does the participant
expect that listening to the recordings at home will be a
burden?
The Treatment Preference and Experience-Therapist
Scale (TPE-TS) allows therapists, before treatment starts, to
score their treatment experience with both PE and EMDR
and their personal preference to start with PE and EMDR
with this particular patient, on a VAS-scale from 0 to 100.
Post treatment the therapist again scores his/her personal
preference to use PE and EMDR with this particular patient
using the same scale. Psychometric evaluations are not
available.
The Burden Scale – Participant Form (BS-PF) assesses
burden in participants before (expected) and after (experi-
enced) treatment in both conditions, PE and EMDR. Before
treatment the participants responds on a 10-point Likert-
type Scale (‘no, not at all’ to ‘yes, very much’) to the following
questions: (1) Do you fear treatment?, (2) Are you hesitant to
have this treatment?, and (3, only for PE) Do you expect that
listening to the recordings at home will be a burden? After
treatment the participant responds on a 10-point VAS (‘no,
not at all’ to ‘yes, very much’) to the questions: (1) Do you
feel that afterwards the treatment was less burdensome than
you had expected?, (2) Was the treatment much of a burden
to you?, (3) How much of a burden was it to listen to recor-
dings at home? No psychometric evaluations are available.
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The Credibility Scale - Participant Form (CS–PF) assesses
credibility before and after treatment in both conditions PE
and EMDR. Participants respond on a 10-point VAS (‘no,
not at all’ to ‘yes, very much’) to the statements: (1) This
treatment seems logical to me, (2) This treatment seems
scientific to me, (3) If I have a PTSD, I think this treatment
will help me, and (4) If a close friend or relative has PTSD,
I would recommend this therapy to them. There are no
psychometric evaluations available.
The Harm Expectancy session ratings assess the treat-
ment harm expectancies (before the session) and experi-
enced harm (after the session) in two sessions (sessions 2
and 3). Participants respond on a 10-point VAS (‘no, not at
all’ to ‘yes, very much’) to the questions, describing
expected or actually experienced fear of going crazy,
panicking and losing control, panicking and drop out of
the session, or yet another harm expectancy or harm
experience.
The T.TIP Demographic questionnaire (TDQ) assesses
basic personal, social and medical data as predictors of
treatment outcome variables: 1) age; 2) date of birth; 3)
country of birth (participant, father, mother); 4) highest
level of achievement in education; 5) daily housing/living
situation; 6) DSM-IV-TR diagnoses; 7) substance abuse
or dependence; 8) current medication; 9) years of illness
of psychosis and PTSD.
The Self-Esteem Rating Scale - Short form(SERS-SF)
[121] assesses the mediator/moderator variable of self
esteem on treatment outcome. The 20-item SERS-SF,
with its positive and negative self-esteem subscales,
appears to be a valid and reliable self-esteem measure
for individuals with severe mental health problems. The
original 40-item SERS was reduced to a psychometrically
good 20 item version of the SERS, the SERS-SF. The
SERS-SF [121] has 10 positive and 10 negative items on
self-esteem. The two scales have excellent internal
consistency (α = .91 positive scale; α = .87 negative
scale). The test–retest reliability of both scales is high
(r =0.90; r =0.91). The SERS total score correlated highly
with both scales (r = 0.72 and r = 0.79), indicating good
convergent validity.
The Personal Beliefs about Illness Questionnaire –
Revised version (PBIQ-R) [51] assesses the mediator/
moderator variable of cognitions about, and coping with,
being ill on treatment outcome. The original PBIQ was a
16-item scale developed to assess people’s appraisals of a
psychotic illness in five domains, namely (1) control over
illness; (2) self as illness; (3) illness as an impediment to
the attainment of goals; (4) humiliation and guilt, and
(5) need for social containment. A revised 29-item scale
(PBIQ-R) measures five different modes of experience
following a psychotic illness: shame (six items); loss
(seven items); entrapment in psychosis (six items); control
over illness (five items); and social marginalization/group
fit (five items). Participants respond to statements (for
example, ‘I will always need medical care’) by choosing
between: ‘strongly disagree’, ‘diagree’, ‘agree’ or ‘strongly
agree’. The PBIQ has no total score. The PBIQ-R has good
predictive validity for relapse as a result of negative
appraisals of illness and coping skills [122].
The Posttraumatic Cognitions Inventory (PTCI) [93] is
assessed as a mediator/moderator variable on treatment
outcome. For a description, see the section on Measure-
ments – effects of treatment on psychopathology and
cost effectiveness.
The Davos Assessment of Cognitive Biases Scales
(DACOBS) [123] assesses the mediator/moderator variable
of cognitive biases in psychoses on treatment outcome.
Cognitive problems and biases play an important role in
the development and continuation of psychosis. The
DACOBS has been developed as a self-report measure of
these deficits and processes. It assesses seven statistically
independent deficient thought processes. Each factor is
represented with six items: jumping to conclusions,
confirmation bias/dogmatism, selective attention for threat,
self as target, theory of mind problems, subjective cognitive
failure and avoidance behavior. Each item is a statement
that is scored on a 7-point Likert scale within a two-week
time frame. Reliability was good (α = 0.90; split-half reliabi-
lity = 0.92; test-retest reliability = 0.86). The DACOBS
distinguishes between schizophrenia spectrum patients and
normal control subjects. It is reliable and valid and may be
used in research.
The Auditory Verbal Hallucinations – Basic Assump-
tions Scale (AVH-BAS; van den Berg etal., publication in
preparation) assesses the mediator/moderator variable of
participants' basic assumptions about voice hearing on
treatment outcome. The AVH-BAS is especially deve-
loped for this RCT. In another study outside of T.TIP
responses of 176 voice-hearing patients were assessed on
several items that reflect cognitive and emotional
appraisal of voices. After item- and factor-analysis, 14
AVH-BAS-items remained that assess cognitive assump-
tions about voices. Four factors have shown to be rele-
vant: (1) negative self-esteem, (2) guilt, (3) powerlessness
and (4) danger/threat. Initial analyses suggest that the
AVH-BAS may be a reliable and valid instrument.
The Memory Characteristics Questionnaire – Revised
Form (MCQ-RF) [119], which was adapted for the present
study, assesses aspects of the traumatic memory as a
mediator/moderator variable and its influence on treat-
ment outcome. The MCQ-RF is administered within treat-
ment sessions. The MCQ-RF assesses self-reported
characteristics of trauma memories. The original MCQ
has a test-retest reliability total scale of r =. 86. In T.TIP
we used a shortened version (three items) of the
re-experiencing subscale (test-retest reliability r = .86):
sense of reliving, sense of here and now, and perceptual
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elements. We added one item about memory-related emo-
tions (for example, dissociation, anxiety, anger, guilt and
depression) and one item about memory-related image
characteristics (for example, color, light and movement).
Participants were asked to rate their trauma memories for
each of the items on a 0 to 100 scale.
The Medical Outcome Studies - Social Support Survey
(MOS-SSS) [120] assesses experienced social support as a
possible predictor variable of treatment outcome. The sur-
vey consists of four separate social support subscales and
an overall functional social support index. A higher score
for an individual scale or for the overall support index in-
dicates more support. Overall index internal-consistency
reliability: α=0.97, one-year test-retest stability= 0.78. For
our purposes only the subscales ‘emotional support’ (ES)
and ‘instrumental support’ (IS) are administered to the
participants. On a Likert type scale from 1 (‘none of the
time’) to 5 (‘All of the time’) participants respond to four
ES-items: (1) Someone you can count on to listen to you
when you need to talk, (2) Someone to give you informa-
tion to help you understand a situation, (3) Someone to
give you good advice about a crisis, (4) Someone to con-
fide in or talk to about yourself or your problems, and to
four IS-items (5) Someone whose advice you really want,
(6) Someone to share your most private worries and fears
with, (7) Someone to turn to for suggestions about how to
deal with a personal problem and (8) Someone who
understands your problems.
The internal-consistency reliability and one-year stability
for subscales ES and IS: α=0.96, stability =0.72 [120].
Fidelity checks
The interrater reliability of interview assessments with the
CAPS, PSP and SCI-SR remission tool is accounted for
ingroup wise sessions for interrater reliability enhance-
ment and interrater reliability measurements. Interrater
reliability measurements will be carried out monthly, by
presenting cases to the research assistants for scoring. All
assessments that research assistants will perform at T0,
T2, T6 and T12 are presented in a written report, to be
reviewed by the researchers.
Therapists receive four days of training in each treat-
ment protocol, that is, PE and EMDR. All treatment ses-
sions will be videotaped. A selection will be rated for
treatment fidelity. All therapists will be supervised by
highly skilled professionals (AvM, AdJ and CdR, respect-
ively) to evaluate, guide and approve the case conceptuali-
zations and treatment interventions. Monthly, four-hour
group supervision supports the therapist for the whole
duration of the experimental intervention.
Every session the therapist will fill out a self-report
questionnaire about the elements and the steps in the
treatment protocol. Deviations from the protocol will be
reported to the supervisor.
Therapist ratings
During the whole process of training and treatment,
assessments will be carried out of therapists' opinions and
expectations regarding the credibility and burden of treat-
ment. As indicated in the Instruments section the T-TAQ
is administered, comprising the ITTEQ-TF, the CS-TF and
the BS-TF. The ITTEQ-TF is integrated into the training
and supervision on PE and EMDR and is rated at different
levels: before treatment training ('prior'), halfway through
training ('theory'), after training ('first practice'), in therapist
group supervision session number four ('novice'), at the
end of the supervision series ('competent') and at the half
year follow up ('expert'). The session versions of both the
CS-TF and BS-TF (CS-TSF and BS-TSF) will be used add-
itionally within treatment sessions one and eight.
The TPE-TS is administered to therapists before and
after treatment of each participant.
Analyses
The primary outcome on the PTSD measures will be ana-
lyzed using Linear Mixed Models (LMM) with the base-
line value as a covariate. LMM will also be used with the
secondary outcome measures. Sensitivity and specificity of
the screener will be calculated with Receiver Operating
Characteristic curves. The predictors will be assessed with
(logistic) regression analysis. The moderator and mediator
analyses will be calculated with 5,000 bootstraps [124].
The association between working memory and the out-
come of therapy is performed by analysis of covariance
(ANCOVA’s) and multiple regression analysis. The ESM
data will be analyzed by multilevel linear regression mod-
eling using STATA. In case of an effective treatment a
cost-effectiveness analysis will be performed. The incre-
mental cost-effectiveness ratios (ICERs) are considered to
be a single-point estimate of an underlying continuum.
Acceptability curves are produced with bootstrap simula-
tions and confidence intervals. The outcome will be costs
in Euro’s per QALY and the costs in Euro’s per day with-
out PTSD gained. If no intervention is effective, which is
not expected, a cost-minimization calculation will be
done.
Discussion
This present so called ‘T.TIP trial’ has several strengths that
have the potential of making the T.TIP trial a forerunning
experiment.
First, it is hypothesized that the T.TIP trial will make it
possible to calibrate an efficacious and efficient short
screening tool for assessing PTSD in the group of patients
with psychosis. Given the fact that PTSD is underdiagnosed
in this patient population [19,20], an instrument that
quickly, safely and accurately assesses the risk of PTSD may
be a significant aid to clinical practice.
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The main goal of the study is to treat PTSD in patients
with psychosis. The comparison of two trauma-focused
treatments to a waiting list condition will provide answers
about the effectiveness of these trauma-focused treatments
on PTSD symptoms. This is the first controlled study that
directly assesses the effectiveness of two guideline-
recommended trauma-focused treatments in this severely
mentally ill population that is generally excluded from cli-
nical trials [29]. Further, it is a large study, including enough
patients to make powerful conclusions. This would be an
important contribution to treatment options for people
suffering from psychosis and PTSD, as PTSD symptoms
negatively influence the level of functioning and quality of
life in patients with psychosis [9,10]. Conceivably, reducing
these symptoms will be of great personal value to patients
with psychosis who suffer from the consequences of expo-
sure to traumatic events.
What is more, the study is aimed at establishing whether
these treatments can be applied safely in this patient popu-
lation. This is important for the implementation of the
treatments, given the fact that clinicians are often hesitant
to address issues of exposure to traumatic events in this
population because they fear deterioration and crisis
[23,24]. Interestingly, in this aspect, we applied short-term
(eight sessions) ‘basic’ manualized treatment to this popula-
tion, without any pre-treatment interventions, such as
emotion-regulation, skills training, or stress management.
Should these standard trauma-focused treatments prove to
be safe, this will strengthen their implementation in clinical
practice. A strength of the study is also that it is a multi-
center trial, which will enhance the internal and external
validity of the interventions.
In addition to PTSD-symptoms and safety, we also stud-
ied effects of treatments on psychopathology severity, espe-
cially psychotic symptoms. By studying several variables
during treatment, we will be able to disentangle the com-
plex interactions between traumatic events, PTSD and
psychosis [9-13] and identifying mediators, moderators and
predictors of treatment outcome. This is important from a
theoretical point of view, but also from a clinical perspec-
tive. It will provide practical guidelines for diagnosis and
treatment of PTSD in the population of patients with
psychosis. One limitation is that only patients are included
in the intervention part of the present studywho suffer from
psychosis and at the same time meet all PTSD criteria
according to the DSM-IV-TR. Should the results on tertiary
objectives indicate that there are links between the trauma
characteristics and the characteristics of psychosis in this
particular group, then these results cannot be generalized
automatically to the general population of patients with
psychosis (with individuals who have no PTSD symptoms
or subthreshold PTSD).
Another important part of the study is the measurement
of cost-effectiveness. When PTSD and other symptoms of
psychopathology decrease as a result of treatment, it can be
expected that patients consume less care, and thereby di-
minish health costs.
Trial status
Currently screening and recruiting for participants.
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